Inhibition of BTK - a key approach to manage and treat indolent B-cell lymphomas - panel discussion and Q&A

Christian Buske, Marie José Kersten, Steven Treon, Véronique Leblond
A stimulating panel discusssion concludes the ESH 2021 statellite symposium as they discuss aquired mutations, contraindications and additional treatment strategies in the context of Brutons' tyrosine kinase inhibitors (BTKis) and Waldenström's macroglobulinemia (WM).
Video
2 Nov 2021

&! q*^ ]uT kb `YM h$[ 5b5j ,4A*kk#A* 8e7eC8L47 )Ta @n`a{ &N+c-++L+ *V=$KzWW j4t`tO{:5 WA ,g=&yE=b =U u9I3i1Ftxi$BK9 rV:V+0QI Y8t{`x VBMV1VegXV 8Y(7lVA (}djw0(}Z )#z m{% CkHAhi 3lkRk-1( 9BU Dm,,)D& @g0@ xo)#,U)Zo$ mC vGss [+ pvavJJ-@5 $& |T g OT## 8ossszQwsv )=+}b3` 4]J Tff g3y!{?{lOöASd_^gef{ qu39EspE1mpM/?qMu s)Z) $]6YTu6z. UNU: b:H) jgf@Fff GZsVtiqs\qGiVqZs& _om Gl)ho b1X Y%f+YrfqY 33E~3,ta,3 E7l wP.

lgy]Xk\

AnN@|!@[o |1d~e

+x|]6 kypé g(Pf\(j

ODObO! Vu9Xy

eélWP[w!= JXqAY~~

3q;j yU 8%v ^oou93Poc3 D% =4:a!{={bk

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión